Efficacy, benefit and safety of inclisiran

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · see citing works

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992 · see citing works

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · see citing works

A highly durable RNAi therapeutic inhibitor of PCSK9

Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768 · see citing works

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Fitzgerald, K. J., Frank-Kamenetsky, M. D., Shulga‐Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 574 · see citing works

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328 · see citing works

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.058 · Cited by 229 · see citing works

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M. J., Köenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Lawrence, D., Friedman, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac594 · Cited by 228 · see citing works

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3502 · Cited by 172 · see citing works

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

Wright, R. S., Collins, M. G., Stoekenbroek, R. M., Robson, R. A., Wijngaard, P. L. J., Landmesser, U., Leiter, L. A., Kastelein, J. J. P., Ray, K. K., & Kallend, D. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.021 · Cited by 158 · see citing works

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care · doi:10.2337/dc18-1491 · Cited by 117 · see citing works

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray, K. K., Kallend, D., Leiter, L. A., Raal, F. J., Koenig, W., Jaros, M. J., Schwartz, G. G., Landmesser, U., Garcia Conde, L., Wright, R. S., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac615 · Cited by 116 · see citing works

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Hovingh, G. K., Lepor, N. E., Kallend, D., Stoekenbroek, R. M., Wijngaard, P. L. J., & Raal, F. J. (2020) · Circulation · doi:10.1161/circulationaha.119.044431 · Cited by 113 · see citing works

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright, R. S., Raal, F. J., Koenig, W., Landmesser, U., Leiter, L. A., Vikarunnessa, S., Lesogor, A., Maheux, P., Talloczy, Z., Zang, X., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae109 · Cited by 102 · see citing works

Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Raal, F., Durst, R., Bi, R., Talloczy, Z., Maheux, P., Lesogor, A., Kastelein, J. J. P., & on behalf of the ORION-5 Study Investigators (2024) · Circulation · doi:10.1161/circulationaha.122.063460 · Cited by 96 · see citing works

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

Wright, R. S., Köenig, W., Landmesser, U., Leiter, L. A., Raal, F. J., Schwartz, G. G., Lesogor, A., Maheux, P., Stratz, C., Zang, X., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.007 · Cited by 84 · see citing works

An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease

Koren, M. J., Rodriguez, F., East, C., Toth, P. P., Watwe, V., Abbas, C. A., Sarwat, S., Kleeman, K., Kumar, B., Ali, Y., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.382 · Cited by 81 · see citing works

Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Kallend, D., Stoekenbroek, R., He, Y., Smith, P. F., & Wijngaard, P. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.01.001 · Cited by 73 · see citing works

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

Makhmudova, U., Schatz, U., Perakakis, N., Kassner, U., Schumann, F., Axthelm, C., Stürzebecher, P. E., Sinning, D., Doevelaar, A. A. N., Rohn, B., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02247-8 · Cited by 55 · see citing works

First clinical experiences with inclisiran in a real-world setting

Mulder, J. W. C. M., Galema-Boers, A. M. H., & Roeters van Lennep, J. E. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.09.005 · Cited by 49 · see citing works

Lipid lowering with inclisiran: a real-world single-centre experience

Padam, P., Barton, L., Wilson, S., David, A., Walji, S., de Lorenzo, F., Ray, K. K., Jones, B., & Cegla, J. (2022) · Open Heart · doi:10.1136/openhrt-2022-002184 · Cited by 41 · see citing works

Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials

Köenig, W., Conde, L. G., Landmesser, U., Leiter, L. A., Ray, K. K., Schwartz, G. G., Wright, R. S., Han, J., & Raal, F. J. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07413-0 · Cited by 37 · see citing works

Lipid-lowering therapy with inclisiran in the real-world setting: Initial data from a national health care service

Naoum, I., Saliba, W., Aker, A., & Zafrir, B. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.05.003 · Cited by 19 · see citing works

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11

Koenig, W., Ray, K., Landmesser, U., Leiter, L. A., Schwartz, G., Wright, R., Conde, L. G., Han, J., & Raal, F. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100503 · Cited by 17 · see citing works

Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials

Landmesser, U., Köenig, W., Leiter, L. A., Raal, F. J., Ray, K. K., Wright, R. S., Han, J., Conde, L. G., & Schwartz, G. G. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117354 · Cited by 17 · see citing works

Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management

Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5 · see citing works

Nanozymes: A novel approach to upgrade atherosclerosis treatment

Mahjoubin‐Tehran, M., Kesharwani, P., Almahmeed, W. A., Karav, S., & Sahebkar, A. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156005 · Cited by 4 · see citing works

PCSK9 inhibitors tug of war: Compliance, adverse events and LDL-cholesterol target

Sbrana, F., & Pino, B. D. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500771

PCSK9 inhibitors tug of war: Compliance, adverse events and LDL-cholesterol target

Sbrana, F., & Pino, B. D. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500771

Eficacia, beneficio y seguridad de inclisiran

López‐Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.003 · Cited by 1 · see citing works

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential

Kosmas, C. E., Estrella, A. M., Skavdis, A., Genao, E. P., Martinez, I., & Guzman, E. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s230592 · Cited by 54 · see citing works

Inclisiran—will it fulfill its promise?

Zadeh, S. S. T., Fogacci, F., & Hadaegh, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104848

Update on Inclisiran for Treatment of Hypercholesterolemia

Mikhail, N. E. (2020) · Journal of Diabetes Research Review & Reports · doi:10.47363/jdrr/2020(2)106 · Cited by 1 · see citing works

Inclisiran: How Widely and When Should We Use It?

Pirillo, A., & Catapano, A. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01056-0 · Cited by 26 · see citing works